This approach effectively controls EBV-related tumors, targets and efficiently eliminates EBV-related tumor cells through the FasL and TRAIL pathways and promotes the expansion of EBV antigen-specific CD4 and CD8 T cells [87]. Here, FASLG is linked to neoplasm.